Myocarditis induced by durvalumab in a patient with hepatocellular carcinoma: A case report
Abstract Durvalumab is an immune checkpoint inhibitor that targets PD-L1 and is used for malignancies such as hepatocellular carcinoma. Although effective, it may cause immune-related adverse events, including rare cases of myocarditis (0.06% to 1%), which usually appear early. This complication res...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer
2025-10-01
|
| coleção: | Saudi Pharmaceutical Journal |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1007/s44446-025-00041-3 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|